Androgen Deprivation Therapy News and Research

RSS

Prostatectomy plus radiotherapy associated with greater survival in prostate cancer patients

High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective than the other.

25 Sep 2018

Study: Blood test can predict response of advanced prostate cancer patients to treatments

An international collaborative study between Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden and Epic Sciences is one of the first to demonstrate that a blood test can predict how patients with advanced prostate cancer will respond to specific treatments, leading to improved survival.

25 Jul 2018

Genetic sequencing reveals new clues to aggressiveness of prostate cancer

Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common.

20 Jul 2018

Study: Football training could improve bone mineral density in prostate cancer patients

Androgen deprivation therapy for the treatment of prostate cancer can lead to loss of muscle and bone mass.

16 Jul 2018

Study finds byproduct of common prostate cancer drug can stimulate growth of tumor cells

A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic. The findings may provide important information for identifying which patients potentially fare better when treated with an alternate therapy.

26 Jun 2018

Prostate cancer survivors at higher risk of developing chronic diseases, study shows

Prostate cancer survivors taking androgen deprivation therapy (ADT), a treatment commonly used to block the release of male hormones, are at a higher risk of developing chronic diseases, according to new research published this week.

31 May 2018

Researchers shed light on how androgen deprivation therapy increases risk for cardiovascular mortality

Prostate cancer is the most common cancer in men in the US. As the prostate is a testosterone-responsive gland, androgen deprivation therapy is the cornerstone of treatment in these men, with approximately 50 percent of prostate cancer patients starting ADT within a year of diagnosis.

22 May 2018

Exercise and diet can help fight side effects of hormone therapy in prostate cancer patients

Men on hormone therapy for prostate cancer may benefit significantly from hitting the gym with fellow patients and choosing more veggies and fewer cheeseburgers, a new study suggests.

3 Apr 2018

Study reveals impact of prostate cancer on wives and partners of sufferers

Many wives of advanced prostate cancer sufferers feel that their lives are being undermined by their husband's illness, with nearly half reporting that their own health suffered.

19 Mar 2018

Southern Research scientists target mutated protein to combat prostate cancer

Southern Research scientists are exploring how a mutated protein implicated in prostate cancer plays a role in the development of the disease and whether it holds a key to better treatment outcomes.

13 Mar 2018

Research: Men who lack HSD17B4 gene may be more susceptible to treatment-resistant prostate cancer

Cleveland Clinic researchers have confirmed for the first time a mechanistic link between the gene HSD17B4 and deadly, treatment-resistant prostate cancer.

17 Jan 2018

Two new treatments may benefit patients with high risk prostate cancer, trial shows

Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.

8 Sep 2017

Moffitt researchers develop novel drug that may help combat castration-resistant prostate cancer

Prostate cancer is the third most common cause of cancer-related death in men in the United States. It is estimated that 161,360 men will be diagnosed and more than 26,700 men will die from the disease in this year.

12 Jun 2017

Study explores effects of androgen deprivation therapy on overall geriatric health

Androgen drives many prostate cancers. But the body uses androgen for muscle growth and maintenance, among other functions.

5 Jun 2017

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

A clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%.

5 Jun 2017

Precise delivery of HDR brachytherapy provides good quality of life to prostate cancer patients

Doctors have found that treating prostate cancer with a single, high dose of radiation delivered precisely to the site of the tumor results in good quality of life and fewer trips to the hospital, with adverse side effects that are no worse than if the radiation treatment had been given in several lower doses.

8 May 2017

Combined treatment regimen shows early promise in eliminating metastatic prostate cancer

In the past, all forms of metastatic prostate cancer have been considered incurable. In recent years, the FDA has approved six drugs for men with metastatic disease, all of which can increase survival.

18 Apr 2017

Clinical study examines impact of yoga on side-effects caused by prostate cancer treatment

Men who attended a structured yoga class twice a week during prostate cancer radiation treatment reported less fatigue and better sexual and urinary function than those who didn't, according to a clinical trial led by the Perelman School of Medicine at the University of Pennsylvania.

6 Apr 2017

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational agent for postmenopausal women with osteoporosis.

3 Apr 2017

New analysis shows correlation between testosterone-lowering therapy for prostate cancer and dementia

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (ADT) - a testosterone-lowering therapy and a common treatment for the disease - and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.

30 Mar 2017